Nifty
Sensex
:
:
25323.55
82605.43
178.05 (0.71%)
575.45 (0.70%)

Pharmaceuticals & Drugs - Domestic

Rating :
73/99

BSE: 506820 | NSE: ASTRAZEN

9148.50
15-Oct-2025
  • Open
  • High
  • Low
  • Previous Close
  •  9121
  •  9213.5
  •  9051.5
  •  9121.50
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  7740
  •  70592902
  •  10691
  •  6220

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 22,944.50
  • 125.13
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 22,407.80
  • 0.35%
  • 28.01

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 75.00%
  • 1.32%
  • 15.17%
  • FII
  • DII
  • Others
  • 3.03%
  • 4.51%
  • 0.97%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.78
  • 16.10
  • 19.61

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 31.50
  • 13.39
  • 8.99

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 36.22
  • 4.40
  • 5.24

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 108.36
  • 107.86
  • 99.06

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 20.53
  • 20.31
  • 21.60

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 62.44
  • 65.09
  • 64.61

Earnings Forecasts:

(Updated: 11-10-2025)
Description
2024
2025
2026
2027
Adj EPS
46.3
P/E Ratio
197.59
Revenue
1716.29
EBITDA
253.97
Net Income
115.74
ROA
8.92
P/B Ratio
29.69
ROE
15.62
FCFF
94.05
FCFF Yield
0.42
Net Debt
-500.97
BVPS
308.14

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated
Description
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Sep 24
Sep 23
Var%
Net Sales
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Expenses
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
EBITDA
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
EBIDTM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Other Income
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Interest
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Depreciation
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PBT
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Tax
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PAT
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PATM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
EPS
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

News Update:


  • Astrazeneca Pharma gets CDSCO’s nod to import Trastuzumab Deruxtecan
    4th Oct 2025, 13:11 PM

    The medicine is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options

    Read More
  • Astrazeneca Pharma I - Quarterly Results
    14th Aug 2025, 14:09 PM

    Read More
  • AstraZeneca Pharma India to launch Eculizumab (Soliris)
    7th Aug 2025, 15:57 PM

    Eculizumab (Soliris) is indicated for the treatment of patients with PNH and aHUS to inhibit complement

    Read More
  • AstraZeneca Pharma India gets nod to market Durvalumab Solution
    15th Jul 2025, 10:12 AM

    The company has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.